TScan Therapeutics (NASDAQ:TCRX) Given “Outperform” Rating at Wedbush
Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $7.00 price target on the stock. TCRX has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price […]
Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $7.00 price target on the stock. TCRX has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price […]
